CN115043843A - 3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形 - Google Patents

3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形 Download PDF

Info

Publication number
CN115043843A
CN115043843A CN202210369530.8A CN202210369530A CN115043843A CN 115043843 A CN115043843 A CN 115043843A CN 202210369530 A CN202210369530 A CN 202210369530A CN 115043843 A CN115043843 A CN 115043843A
Authority
CN
China
Prior art keywords
methyl
ponatinib
crystalline
xrpd
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210369530.8A
Other languages
English (en)
Chinese (zh)
Inventor
C.K.默里
L.W.罗扎马斯
J.J.沙伯
P.夏尔马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceuticals USA Inc
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115043843(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Publication of CN115043843A publication Critical patent/CN115043843A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202210369530.8A 2012-12-12 2013-12-12 3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形 Pending CN115043843A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US61/736,543 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US61/737,007 2012-12-13
US201361788208P 2013-03-15 2013-03-15
US61/788,208 2013-03-15
CN201380072027.5A CN105188701A (zh) 2012-12-12 2013-12-12 3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形
PCT/US2013/074571 WO2014093579A2 (en) 2012-12-12 2013-12-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380072027.5A Division CN105188701A (zh) 2012-12-12 2013-12-12 3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形

Publications (1)

Publication Number Publication Date
CN115043843A true CN115043843A (zh) 2022-09-13

Family

ID=50929140

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210369530.8A Pending CN115043843A (zh) 2012-12-12 2013-12-12 3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形
CN201380072027.5A Pending CN105188701A (zh) 2012-12-12 2013-12-12 3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380072027.5A Pending CN105188701A (zh) 2012-12-12 2013-12-12 3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形

Country Status (9)

Country Link
US (9) US9493470B2 (https=)
JP (5) JP6447508B2 (https=)
CN (2) CN115043843A (https=)
CA (3) CA3022250A1 (https=)
CL (1) CL2015001643A1 (https=)
HK (1) HK1218878A1 (https=)
MX (11) MX391445B (https=)
NZ (1) NZ709648A (https=)
WO (2) WO2014093583A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2495016T1 (sl) 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9725454B2 (en) 2013-07-04 2017-08-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
EA201991197A1 (ru) * 2016-12-15 2020-01-13 Ариад Фармасьютикалз, Инк. БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
US11072620B2 (en) 2017-06-20 2021-07-27 Apotex Inc. Crystalline forms of Ponatinib hydrochloride
PT3774844T (pt) * 2018-04-02 2023-03-28 Stealth Biotherapeutics Inc Dipeptídeos cristalinos úteis na síntese de elamipretida
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
CN113677346A (zh) 2018-11-01 2021-11-19 希洛斯医药品股份有限公司 周期蛋白依赖性激酶7(cdk7)的抑制剂
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770129A (zh) * 2009-10-30 2012-11-07 阿里亚德医药股份有限公司 治疗癌症的方法和组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) * 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
ES2240202T3 (es) * 1999-11-08 2005-10-16 Schering Corporation Procedimiento de preparacion de n-(4-hidroxifenil)-n'-(4'-aminofenil)piperazina.
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
AR041992A1 (es) 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
JP2007515400A (ja) 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
WO2005056571A1 (en) * 2003-12-05 2005-06-23 Biovitrum Ab Improved synthesis of 2-substituted adenosines
EP1737462B1 (en) 2003-12-24 2008-07-30 AstraZeneca AB Pyrimidines with tie2 (tek) activity
EP1737463B1 (en) 2003-12-24 2008-12-03 AstraZeneca AB Pyrimidines with tie2 (tek) activity
BRPI0508790A (pt) 2004-04-07 2007-09-04 Applied Research Systems ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
EP1893605A2 (en) 2005-03-31 2008-03-05 AstraZeneca AB Saminopyrimidine derivates with tie2 inhibiting activity
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
CA2618513A1 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
SI2495016T1 (sl) * 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
BRPI0710331A2 (pt) 2006-05-08 2012-03-20 Ariad Pharmaceuticals, Inc Compostos heteroarila monocíclicos para tratamento de câncer e composição
AU2007249924B2 (en) 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20100273772A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CA2832483A1 (en) * 2011-04-07 2012-10-11 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
MX2013011589A (es) 2011-04-07 2013-12-16 Ariad Pharma Inc Metodos y composiciones para tratar enfermedad de parkinson.
US20150105377A1 (en) 2012-04-25 2015-04-16 Ariad Pharmaceuticals, Inc. Methods and Compositions for RAF Kinase Mediated Diseases
CA3022250A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770129A (zh) * 2009-10-30 2012-11-07 阿里亚德医药股份有限公司 治疗癌症的方法和组合物

Also Published As

Publication number Publication date
CA3167093A1 (en) 2014-06-12
JP7042175B2 (ja) 2022-03-25
WO2014093579A2 (en) 2014-06-19
US20210277010A1 (en) 2021-09-09
MX2021002258A (es) 2021-05-27
US20170190707A1 (en) 2017-07-06
US20190169196A1 (en) 2019-06-06
WO2014093583A2 (en) 2014-06-19
JP6447508B2 (ja) 2019-01-09
US9493470B2 (en) 2016-11-15
WO2014093579A3 (en) 2014-07-10
JP2022037122A (ja) 2022-03-08
JP2016503010A (ja) 2016-02-01
CA2815506C (en) 2018-12-11
CA3022250A1 (en) 2014-06-12
MX2021002261A (es) 2021-05-27
US20210277011A1 (en) 2021-09-09
US11192896B2 (en) 2021-12-07
US10125136B2 (en) 2018-11-13
US20210277012A1 (en) 2021-09-09
MX2021002253A (es) 2021-05-27
NZ709648A (en) 2020-05-29
JP2018168191A (ja) 2018-11-01
CL2015001643A1 (es) 2015-10-02
MX2021002255A (es) 2021-05-27
JP7352841B2 (ja) 2023-09-29
WO2014093583A3 (en) 2014-08-07
MX2021002259A (es) 2021-05-27
JP2026010061A (ja) 2026-01-21
US11384086B2 (en) 2022-07-12
MX2021002257A (es) 2021-05-27
MX2021002264A (es) 2021-05-27
MX391445B (es) 2025-03-21
HK1218878A1 (zh) 2017-03-17
US10662197B2 (en) 2020-05-26
US20150315194A1 (en) 2015-11-05
MX2021002254A (es) 2021-05-27
JP2023179498A (ja) 2023-12-19
MX2021002256A (es) 2021-05-27
MX359147B (es) 2018-09-17
US11192897B2 (en) 2021-12-07
CA2815506A1 (en) 2014-06-12
US11192895B2 (en) 2021-12-07
US20210340149A1 (en) 2021-11-04
CN105188701A (zh) 2015-12-23
US20210024527A1 (en) 2021-01-28
US11279705B2 (en) 2022-03-22
MX2015007578A (es) 2016-03-21
US20240083902A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
JP7352841B2 (ja) ３－（イミダゾ［１，２－ｂ］ピリダジン－３－イルエチニル）－４－メチル－Ｎ－｛４－［（４－メチルピペラジン－１－イル）メチル］－３－（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
JP2019530719A (ja) ４−（２−（（１ｒ，２ｒ）−２−ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール−６−イルオキシ）−ｎ−メチルピコリンアミドの結晶形
AU2023219845B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N- {4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
HK40080449A (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US20130150450A1 (en) Novel solid forms of tacedinaline
WO2012003413A1 (en) Novel solid forms of tacedinaline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080449

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20250403

Address after: Miami, USA

Applicant after: TAKEDA PHARMACEUTICALS NORTH AMERICA, Inc.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Applicant before: ARIAD PHARMACEUTICALS, Inc.

Country or region before: U.S.A.

TA01 Transfer of patent application right